Page 22 - Linical Evolution News Today

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.

A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.

RSG Arrive is intended to increase clinical trial participation by offering ground transport, plane rides, hotels, visa procurement, and other services.

The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.

To fully reap the benefits of tech advances, a company leader advises, a life-sciences firm must embrace change and connection throughout the operation.

According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.

A leader from the pharmaceutical firm talks about some of the most impactful technologies and shares a number of notable advancements made by the company.

A study from Climedo Health aims at revealing the growing influence the decentralized format is enjoying across the industry and what might lie ahead.